Investigational bulking agent for SUI provides durable efficacy at1 year
After 1 year of follow-up, women with stress urinary incontinence treatedwith an investigational bulking agent containing ethylene vinyl alcoholdissolved in a dimethyl sulfoxide carrier (EVOH/DMSO, Uryx) are demonstratingdry and improved outcomes more often than controls receiving injectablecollagen (Contigen), investigators from a multicenter study reported yesterday.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.